Catalogue des publications

[EN] Fexinidazole versus NECT for stage 2 Trypanosoma brucei gambiense human African trypanosomiasis: a multicentre, randomised, phase III trial

This multicentre randomised phase III trial demonstrates non-inferiority of oral fexinidazole compared to the standard NECT regimen for stage 2 HAT, with a cure rate of 95.2% vs 93.8% at 18 months.

Fexinidazole versus NECT for stage 2 Trypanosoma brucei gambiense human African trypanosomiasis: a multicentre, randomised, phase III trial

Marie-Claire Mukendi Ngoy, Gracia Tshibangu Lukusa, Mukendi Ngoy MC, Tshibangu Lukusa G

This multicentre randomised phase III trial demonstrates non-inferiority of oral fexinidazole compared to the standard NECT regimen for stage 2 HAT, with a cure rate of 95.2% vs 93.8% at 18 months.